BioNTech says collaboration with Pfizer remains unchanged
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/19/2026
- Nasdaq climbs as chip and AI-linked stocks bounce back
- U.S. economy is "booming," JPMorgan’s Dimon says
- Musk pledges one share of SpaceX to every U.S. child
- Oil edges higher as investors weigh renewed Houthi attacks on Saudi infrastructure
- Prepare to buy the dip as U.S. stock selloff nears its end: Morgan Stanley
Tweet
Share
E-mail
The logo of BioNTech is pictured at Biontech's research laboratory for individualised vaccines against cancer in Mainz, Germany, July 27, 2023. REUTERS/Wolfgang Rattay
FRANKFURT (Reuters) -BioNTech said on Thursday that its collaboration with Pfizer has not changed, when asked to comment on a report that Pfizer is looking to sell its stake in the German biotech firm.
"We continue to have a close and strong collaboration," a spokesperson said in a statement, adding that BioNTech would not be commenting on any capital market activities by Pfizer.
(Reporting by Ludwig Burger, editing by Thomas Escritt)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DeepSeek teams up with Huawei to challenge Nvidia
- Canada inflation breaches BoC target as gasoline prices surge
- Eos Energy gains as preliminary Q3 revenue beats Wall Street estimates
Create E-mail Alert Related Categories
General News, ReutersSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
